Menu

A T-Cell Tweak Combats Advanced Breast Cancer

The immunotherapy eliminated a woman’s metastatic lesions and kept her disease-free for two years.

Jun 5, 2018
Ashley Yeager

ISTOCK, MELETIOS VERRASReactivating T cells in a woman with metastatic breast cancer eliminated her tumors, researchers report today (June 4) in Nature Medicine. It is the first time late-stage breast cancer has been successfully treated with T-cell immunotherapy.

“We’re looking for a treatment—an immunotherapy—that can be broadly used in patients with common cancers,” study coauthor Steven Rosenberg, an oncologist and immunologist at the National Cancer Institute (NCI), tells NPR. The result suggests this type of treatment might be possible for other types of solid tumors, including in the colon, rectum, and pancreas.

To develop the treatment, Rosenberg and his colleagues used whole-exome and RNA sequencing to identify point mutations within the genome of a patient’s breast tumor and then isolated tumor-infiltrating lymphocytes from the mass and identified which ones were reactive against mutations in the genes SLC3A2, ECPAS, CADPS2, and CTSB, which were present in her tumor. The researchers then infused into the patient roughly 90 billion tumor-infiltrating lymphocytes that targeted the four mutant genes. In addition, she received treatment with an anti–programmed cell death protein 1 antibody two days before the T-cell transfer, along with antibody infusions three, six, and nine weeks after it. Her tumors disappeared.

Such a result is “an unprecedented response in such advanced breast cancer,” writes Laszlo Radvanyi of the Ontario Institute for Cancer Research in Toronto in an accompanying Nature Medicine News & Views article.

Still, Rosenberg notes to NPR, the treatment won’t work for everyone. Two other patients with breast cancer failed to respond to the therapy. But the approach has helped seven patients, including individuals with colon, liver, or cervical cancer. “Is it ready for prime time today? No,” Rosenberg says. “Can we do it in most patients today? No.” But, “I think it’s the most promising treatment now being explored for solving the problem of the treatment of metastatic, common cancers,” he says.

“This is an illustrative case report that highlights, once again, the power of immunotherapy,” Tom Misteli, director of the Center for Cancer Research at NCI who was not involved in the study, tells Forbes. “If confirmed in a larger study, it promises to further extend the reach of this T-cell therapy to a broader spectrum of cancers.”

June 2019

Living with Bacteria

Can pathogens be converted to commensals?

Marketplace

Sponsored Product Updates

Gyros Protein Technologies introduces Gyrolab E. coli HCP Kit for automated impurity analysis of biotherapeutics
Gyros Protein Technologies introduces Gyrolab E. coli HCP Kit for automated impurity analysis of biotherapeutics
Ready-to-use immunoassay kit increases analytical output and productivity in bioprocess workflows. Kit developed as part of licensing and supply agreement with Cygnus Technologies
IDT launches ultra-high performance CRISPR Cas12a enzyme
IDT launches ultra-high performance CRISPR Cas12a enzyme
IDT’s new CRISPR Cas12a (Cpf1) Ultra enzyme can target new sites within the genome and with greater efficiency
Implen Launches New NanoPhotometer N120: The High Throughput Champion!
Implen Launches New NanoPhotometer N120: The High Throughput Champion!
Implen GmbH is excited to announce the release of the NanoPhotometer® N120, an absorbance based UV/VIS Multi Channel Spectrophotometer.
StemExpress Announces Release of New Frozen Leukopak® to Advance Research
StemExpress Announces Release of New Frozen Leukopak® to Advance Research
To continue to provide new products and services to further advance medical research around the world, today, StemExpress announced the release of their Frozen Leukopak®.